Type 2 diabetic acute myocardial infarction (AMI) patients receiving sodium-glucose cotransporter 2 inhibitors (SGLT2-I) exhibited a significantly reduced inflammatory response. The gene discussed is SLC5A2; the disease is myocardial infarction.